Accipiter Biosciences
Accipiter Biosciences uses computational protein design to develop de novo protein therapies that engage multiple cell-surface receptors and pathways in one stable molecule. Its therapies are designed for complex diseases, including autoimmune disorders and cancer, as an alternative to combination treatments.
Facts
- HQ
- Seattle, Washington, US
- Sectors
- Biotechnology Research
- Founded
- 2023 Seattle business license
- Type
- Corporation Seattle business license
- Employees
- 26
- Registered name
- Accipiter Biosciences Inc Seattle business license
- Stage
- Seed
- Members see funding amounts. .
Is this your organization? Claim it
Accipiter Biosciences raises $12.7M seed from Takeda and Flying Fish Partners to advance de novo protein therapeutics
Accipiter Biosciences announced a $12.7 million seed round led by Takeda and Flying Fish Partners to fund its de novo protein therapeutics platform and advance preclinical immunology and oncology programs, with strategic collaborations already in place with Pfizer and Kite Pharma.
People
See all 4-
Matthew Bick co-founder and Chief Executive Officer
-
Hector Rincon-Arano Co-founder and Chief Scientific Officer
-
Javier Castellanos Co-founder and Chief Technology Officer